CFO sold ~$436K of Gilead Sciences
Scheduled in advanceLoading…
Traded Aug 20, 2026 · Filed Aug 21, 2026
A board member of Gilead Sciences sold $49K of Gilead Sciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$48,997
Shares × reported transaction price
16 days after results of Aug 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $143.44 on Aug 20, 2026, 30% above its 52-week low and 8% below its high, after a 6% rise over the previous 30 trading days
52-week range $110.56 (Oct 2, 2025) to $155.80 (Feb 11, 2026), 73% of the way up, from 251 adjusted closes. 30 trading days earlier: $134.84 on Jul 9, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
FDA approved Sunlenca on Aug 27, 2026, 7 days after this trade.
New use approved (efficacy supplement). Active ingredient: Lenacapavir Sodium. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -0.3% | +0.5% | -0.7% |
| 30 days | +3.2% | +0.6% | +2.6% |
Past results only. Not a forecast.
CFO sold ~$436K of Gilead Sciences
Scheduled in advanceOfficer sold ~$230K of Gilead Sciences
Scheduled in advanceOfficer sold ~$116K of Gilead Sciences
Scheduled in advance